摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[14C]-Casopitant | 414910-27-3

中文名称
——
中文别名
——
英文名称
[14C]-Casopitant
英文别名
Casopitant;(2R,4S)-4-(4-acetyl-1-piperazinyl)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide;4-(S)-(4-acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;GW679769;(2R,4S)-4-(4-acetylpiperazin-1-yl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide
[14C]-Casopitant化学式
CAS
414910-27-3
化学式
C30H35F7N4O2
mdl
——
分子量
616.622
InChiKey
XGGTZCKQRWXCHW-WMTVXVAQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    615.6±55.0 °C(Predicted)
  • 密度:
    1.296±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.3
  • 重原子数:
    43
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    47.1
  • 氢给体数:
    0
  • 氢受体数:
    10

SDS

SDS:879909ed047249817b6e980df3155a0c
查看

制备方法与用途

casopitant(GW679769)是一种强效的中枢性神经激肽1(NK1)受体拮抗剂,其亲和力为pKi=9.48,具有抗抑郁和止吐作用。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    [14C]-Casopitant盐酸 作用下, 以 乙醚 为溶剂, 生成 Casopitant hydrochloride
    参考文献:
    名称:
    硅路易斯酸与酰基hydr和Danishefsky二烯的高度对映选择性形式的Aza-Diels-Alder反应
    摘要:
    硅路易斯酸3可有效促进酰基hydr与Danishefsky的二烯的高度对映选择性环加成反应(正式的aza-Diels-Alder反应)。反应在环境温度下进行15分钟,并以高收率和高对映选择性生产产物。在绝对立体化学诱导的意义上,已经观察到显着的溶剂依赖性逆转。该方法已应用于神经激肽1受体拮抗剂casopitant的高效和立体选择性合成。
    DOI:
    10.1016/j.tet.2010.03.036
  • 作为产物:
    描述:
    (2R)-2-(4-fluoro-2-methylphenyl)-4-piperidinone L-(+)-mandelate 在 sodium tetrahydroborate 、 甲酸sodium carbonate三乙胺 作用下, 以 乙酸乙酯乙腈 为溶剂, 反应 16.0h, 生成 [14C]-Casopitant 、 (2R)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-hydroxy-N-methylpiperidine-1-carboxamide
    参考文献:
    名称:
    QbD原理在甲磺酸Casopitant甲磺酸盐制造工艺开发中的应用。定义2a,2b和2c阶段某些药物CQA控制策略的过程研究
    摘要:
    Casopitant被鉴定为强效NK 1葛兰素史克(GSK)的抗性药物。它被选为GSK​​广泛药物发现计划的一部分,因为它在许多治疗靶标上具有潜在的活性,例如炎症性肠病,膀胱过度活动症,中枢神经系统疾病等。选择casopitant的甲磺酸盐以使其充分发育。甲磺酸甲磺酸盐的生产工艺是通过遵循“按质量设计”方法开发和优化的,从而开发了以过程理解和风险分析为基础的控制策略,以提高质量保证水平。阶段2a,2b和2c的质量过程参数和规范级别是本文详细讨论的制造过程控制策略的要素。实验设计方法已被广泛用于支持该过程的公认可接受范围的定义。目的是显示为确保最终原料药的质量控制而进行的过程开发研究。
    DOI:
    10.1021/op1000622
点击查看最新优质反应信息

文献信息

  • Chemical compounds
    申请人:——
    公开号:US20040014770A1
    公开(公告)日:2004-01-22
    Formula (1) wherein R represents a halogen atom or a C 1-4 alkyl group; R 1 represents a C 1-4 alkyl group; R 2 represents hydrogen or a C 1-4 alkyl group; R 3 represents hydrogen, or a C 1-4 alkyl group; R 4 represents a trifluorometyl group; R 5 represents hydrogen, a C 1-4 alkyl group or C(0)R 6 ; R 6? represents C 1-4 alkyl, C 3-7 cycloalkyl, NH(C 1-4 alkyl) or N(C1-4alkyl) 2 ; m is zero or an integer from 1 to 3; n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated bytachykinins.
    公式(1)中,R代表卤原子或C1-4烷基;R1代表C1-4烷基;R2代表氢或C1-4烷基;R3代表氢或C1-4烷基;R4代表三甲基基团;R5代表氢、C1-4烷基或C(0)R6;R6代表C1-4烷基、C3-7环烷基、NH(C1-4烷基)或N(C1-4烷基)2;m为零或1至3的整数;n为1至3的整数及其药学上可接受的盐和溶剂化合物;以及它们的制备过程和在通过tachykinins介导的疾病治疗中的用途。
  • Compositions for treating centrally mediated nausea and vomiting
    申请人:Helsinn Healthcare SA
    公开号:EP2722045A2
    公开(公告)日:2014-04-23
    Provided are compositions comprising netupitant for treating nausea and vomiting.
    本发明提供了包含治疗恶心和呕吐的奈普坦的组合物。
  • Compositions and methods for treating centrally mediated nausea and vomiting
    申请人:Helsinn Healthcare SA
    公开号:US10828297B2
    公开(公告)日:2020-11-10
    Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    本文提供了用于治疗或预防化疗、放疗或手术患者恶心和呕吐的组合物和方法。
  • Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl- phenyl -piperidine-1-carboxylic acid [1- (r) (3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety
    申请人:Carletti Renzo
    公开号:US20060217395A1
    公开(公告)日:2006-09-28
    The present invention relates to therapeutic combinations comprising paroxetine or physiologically acceptable salts or solvates thereof and 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts or solvates thereof, to pharmaceutical compositions containing said combinations and their use in the treatment of depression and/or anxiety.
    本发明涉及包含帕罗西汀或其生理学上可接受的盐或溶液和 4-(S)-(4-乙酰基-哌嗪-1-基)-2-(R)-(4--2-甲基-苯基)-哌啶-1-羧酸[1-(R)-(3、5-双三甲基-苯基)-乙基]-甲酰胺或其药学上可接受的盐或溶剂,以及含有上述组合物的药物组合物和它们在治疗抑郁症和/或焦虑症中的用途。
  • Development of Drug Substances as Mixture of Polymorphs: Studies to Control Form 3 in Casopitant Mesylate
    作者:Zadeo Cimarosti、Carlo Castagnoli、Marco Rossetti、Mirka Scarati、Caroline Day、Brendan Johnson、Pieter Westerduin
    DOI:10.1021/op100150b
    日期:2010.11.19
    Polymorphism is characterized as the ability of a drug substance to exist as two or more crystalline phases that have different arrangements and/or conformations of the molecules in the crystal lattice and this can impact the physical properties of a drug substance. In this paper the studies carried out on casopitant mesylate, a NK(1) antagonist developed in GlaxoSmithKline (GSK), are reported.During process development studies it was discovered that what was initially considered a single crystalline phase, Form 1, was actually a mixture of two different forms, Form 1 and Form 3. A retrospective analysis of all the key drug substance batches clearly indicated that Form 3 was always present as minor component in mixture with Form 1. Furthermore any attempt to generate either pure Form 1 or pure Form 3 failed. As a result of this, the project team explored the opportunity to develop the drug substance as a mixture of polymorphs. The studies performed to assess the ability of the manufacturing process to control the amount of Form 3 in the drug substance, according to the Quality by Design principle and the assessment of the impact of this finding on the drug product performance are reported in this paper. Collectively, the data demonstrated that the level of Form 3 in the drug substance (up to a level of 27% w/w) is not a drug substance critical quality attribute (drug substance-CQA) for casopitant mesylate.
查看更多

同类化合物

(R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 ((3S,4R)-3-氨基-4-羟基哌啶-1-基)(2-(1-(环丙基甲基)-1H-吲哚-2-基)-7-甲氧基-1-甲基-1H-苯并[d]咪唑-5-基)甲酮盐酸盐 高氯酸哌啶 高托品酮肟 马来酸帕罗西汀 颜料红48:4 顺式3-氟哌啶-4-醇盐酸盐 顺式2,6-二甲基哌啶-4-酮 顺式1-苄基-4-甲基-3-甲氨基-哌啶 顺式-叔丁基4-羟基-3-甲基哌啶-1-羧酸酯 顺式-6-甲基-哌啶-1,3-二甲酸1-叔丁酯 顺式-5-(三氟甲基)哌啶-3-羧酸甲酯盐酸盐 顺式-4-叔丁基-2-甲基哌啶 顺式-4-Boc-氨基哌啶-3-甲酸甲酯 顺式-4-(氮杂环丁烷-1-基)-3-氟哌 顺式-3-顺式-4-氨基哌啶 顺式-3-甲氧基-4-氨基哌啶 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 顺式-3-(1-吡咯烷基)环丁腈 顺式-3,5-哌啶二羧酸 顺式-3,4-二溴-3-甲基吡咯烷盐酸盐 顺式-2,6-二甲基-4-氧代哌啶-1-羧酸叔丁基酯 顺式-1-叔丁氧羰基-4-甲基氨基-3-羟基哌啶 顺式-1-boc-3,4-二氨基哌啶 顺式-1-(4-叔丁基环己基)-4-苯基-4-哌啶腈 顺式-1,3-二甲基-4-乙炔基-6-苯基-3,4-哌啶二醇 顺-4-(4-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-4-(2-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-3-氨基-4-氟哌啶-1-羧酸叔丁酯 顺-1-苄基-4-甲基哌啶-3-氨基酸甲酯盐酸盐 非莫西汀 雷芬那辛 雷拉地尔 阿维巴坦中间体4 阿格列汀杂质 阿尼利定盐酸盐 CII 阿尼利定 阿塔匹酮 阿哌沙班杂质BMS-591455 阿哌沙班杂质87 阿哌沙班杂质52 阿哌沙班杂质51 阿哌沙班杂质5 阿哌沙班杂质 阿哌沙班杂质 阿哌沙班-d3 阿哌沙班 阻聚剂701 间氨基谷氨酰胺